{"nctId":"NCT04362111","briefTitle":"Early Treatment of Cytokine Storm Syndrome in Covid-19","startDateStruct":{"date":"2020-08-01","type":"ACTUAL"},"conditions":["Cytokine Storm","COVID-19"],"count":32,"armGroups":[{"label":"Anakinra Group","type":"EXPERIMENTAL","interventionNames":["Drug: Anakinra"]},{"label":"Control Group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal saline"]}],"interventions":[{"name":"Anakinra","otherNames":["recombinant human IL-ra (rhIL-1ra)"]},{"name":"Normal saline","otherNames":["NS"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 18 years old or older\n2. Molecular (pcRNA) diagnosis of SARS-CoV-2 infection\n3. Chest imaging studies consistent with Covid-19 pneumonia\n4. Hyperferritinemia (\\>700 ng/ml)\n5. History of fever \\>38 degrees C\n6. Any three of the following:\n\n   1. Elevated d-dimer (\\> 500 ng/ml)\n   2. thrombocytopenia (\\< 130,000/mm3)\n   3. leucopenia (WBC \\<3500/mm3) or lymphopenia (\\<1000/mm3)\n   4. elevated AST or ALT (\\> 2X ULN)\n   5. elevated LDH (\\> 2X ULN)\n   6. CRP \\> 100 mg/L\n\nExclusion Criteria:\n\n1. Participation in other investigational treatment protocols for Covid-19 infection\n2. Culture confirmed active bacterial infection requiring antibiotic therapy\n3. On mechanical ventilation\n4. Previous known hypersensitivity reaction to anakinra\n5. Previous known hypersensitivity reaction to E Coli derived proteins\n6. Pregnant or breast-feeding females","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects Discharged From the Hospital Alive and Without the Need for Mechanical Ventilation.","description":"Percentage of subjects discharged from hospital alive and who did not require intubation and mechanical ventilation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With 25% Change (Decrease) in Cytokine Storm Markers at 48-72 Hours After Dosing With Study Agent","description":"25% change (decrease) in noted baseline elevations of serum ferritin and CRP measured 48-72 hours after following initial dosing of anakinra/placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Without Increase in Oxygen Requirement and no Increase in Oxygen Delivery/Respiratory Support Measures After 48 Hours.","description":"Supplemental oxygen requirement to maintain oxygen saturation \\>90% stable or decreased without escalation of respiratory support measures (addition of CPAP, initiation of mechanical ventilation)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients Requiring Minimal Oxygen Support at Day 10","description":"Percentage of participants requiring no more than 2 L/min nasal canula oxygen to maintain oxygen saturation \\>93% by Day 10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Resolution of Laboratory Markers of Cytokine Storm Syndrome","description":"Normalization or â‰¥ 75% improvement by Day 10 (120 hours) in each (all) of the following laboratory CSS attributes elevated beyond the normal range at randomization: ferritin, d-dimer, CRP, and LDH.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Develop Bacterial or Fungal or Non-Covid-19 Viral Infection","description":"Occurence of new bacterial or fungal or viral infection through the time of hospital discharge or Day 28.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Absence of Supplemental Oxygen Requirement at Day 10","description":"Percentage of participants able to maintain oxygen saturation \\>93% on room air by Day 10","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":15},"commonTop":["Anemia","Acute Renal Failure","Thrombocytopenia","Venous thrombosis","Neutropenia"]}}}